This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
5 ETF Investing Areas for March to Boost Returns
by Sweta Jaiswal, FRM
Here we discuss a few ETFs that can enrich investors' portfolio in March amid a strong wave of optimism surrounding the coronavirus vaccine and introduction of another round of fiscal stimulus.
Stocks Off to a Solid Start in March: 6 Bargain ETF Picks
by Sweta Killa
Given the jump in investors' sentiment, ETFs that still trade at bargain price seem excellent pick.
How Will Biotech ETFs React to Q4 Earnings?
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry post their fourth-quarter earnings releases amid the coronavirus crisis.
Novavax (NVAX) ETFs to Rise on Impressive Coronavirus Vaccine Update
by Sweta Jaiswal, FRM
Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence with multiple mutants.
Can Moderna ETFs Gain on COVID Vaccine Update Against Variants?
by Sweta Jaiswal, FRM
Positive coronavirus vaccine update from Moderna (MRNA) has hogged investors' attention.
A Guide to Biotech ETF Investing Amid the Coronavirus Crisis
by Sweta Jaiswal, FRM
The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.
ETF Areas Thriving During Coronavirus Pandemic
by Sweta Jaiswal, FRM
We highlight some ETF areas that held their ground and gained popularity among investors amid the coronavirus crisis.
Top-Performing Biotech ETFs Amid the COVID-19 Crisis
by Sweta Jaiswal, FRM
The coronavirus pandemic triggered a race to introduce vaccine and treatment, thereby opening up new investing opportunities in the biotech sector in 2020.
Buy 5 High-Beta ETFs Offering Value to Tap Santa Rally
by Sanghamitra Saha
Stimulus deal appears to set the stage for the Santa rally in 2020.
Evergreen Tree of ETFs to Lighten Your Christmas
by Sweta Killa
The Christmas tree of top-ranked ETFs to brighten 2021 is now ready for investors. May it spread cheer!
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
10 Top-Ranked ETFs That Have Outperformed in 2020
by Sweta Killa
The coronavirus outbreak notwithstanding, 2020 has been shaping up as a blockbuster year.
Moderna Vaccine: The Power of mRNA Technology
by Kevin Cook
Warp speed was just the ticket to launch top COVID-19 vaccines -- and a revolution in medicine
Top Two Sector ETFs of Past Decade Still on High Momentum
by Sanghamitra Saha
These ETFs have emerged as one of the top performers in the past decade.
10 Top-Performing ETFs of the Past Decade
by Sanghamitra Saha
These ETFs have emerged as one of the top performers in the past decade.
Biotech ETF (XBI) Hits New 52-Week High
by Sanghamitra Saha
The biotech ETF hits a 52-week high on Nov 27. Can it soar further?
ETF Sectors to Bet on Positive Vaccine News
by Sweta Jaiswal, FRM
The introduction of the coronavirus vaccine is expected to help in the economic recovery, especially for sectors which have taken a hit from the social-distancing and lockdown measures.
Moderna ETFs to Shine on Vaccine News as Outbreak Worsens
by Sweta Jaiswal, FRM
Positive coronavirus vaccine progress from Moderna (MRNA) has hogged investors' attention.
ETFs to Bet on Biden's Potential Presidential Victory
by Sweta Killa
Though the election results are yet to become official, many sectors are expected to benefit on Biden's potential victory.
Should You Invest in the Invesco Dynamic Biotechnology Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Here's Why Healthcare ETFs Are Rallying Post Elections
by Sweta Jaiswal, FRM
Easing worries regarding major policy changes are driving the relief rally in the healthcare and biotech spaces in the post-election period.
ETFs That Gained the Most in One of Best Post-Election Rallies
by Sanghamitra Saha
Wall Street booked remarkable gains a day after the election on hopes of a divided Congress.
Biotech ETF (XBI) Hits a New 52-Week High
by Sanghamitra Saha
This biotech ETF has hit a new 52-week high. Are more gains in store?
How Will Biotech ETFs React to These Q3 Earnings Release?
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their third-quarter earnings releases amid the coronavirus crisis.
Should You Invest in the Invesco Dynamic Biotechnology Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE